Literature DB >> 7031983

Stability of prostacyclin in human plasma and whole blood: studies on the protective effect of albumin.

M A Orchard, C Robinson.   

Abstract

The biological half-life of prostacyclin in Krebs solution, human cell-free plasma or whole blood was measured by bracket assay on ADP-induced platelet aggregation. At 37 degrees C, pH 7.4, plasma and blood reduced the rate of loss of antiaggregatory activity compared with Krebs solution. The protective effect of plasma was greater than that of whole blood. This effect could be partially mimicked by the addition of human or bovine serum albumin to the Krebs solution. The stabilisation afforded by human serum albumin was dependent on the fatty acid content of the albumin, although this was less important for bovine serum albumin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7031983

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I.

Authors:  Y Yui; T Aoyama; H Morishita; M Takahashi; Y Takatsu; C Kawai
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

2.  Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation.

Authors:  R Brandt; A Dembińska-Kieć; R Korbut; R J Gryglewski; J Nowak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-01       Impact factor: 3.000

3.  Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function.

Authors:  D P Mikhailidis; M A Barradas; A M Mikhailidis; H Magnani; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

4.  Serum prostacyclin binding defects in thrombotic thrombocytopenic purpura.

Authors:  K K Wu; E R Hall; E C Rossi; A C Papp
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

5.  Inhibition of vascular epoprostenol (prostacyclin, PGI2) production in vitro by plasma from healthy subjects and patients with severe renal impairment.

Authors:  J M Ritter; M A Orchard; P J Lewis
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

6.  Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs.

Authors:  I J Mackie; R Jones; S J Machin
Journal:  J Clin Pathol       Date:  1984-08       Impact factor: 3.411

7.  Modification of the 31P magnetic resonance spectra of a rat tumour using vasodilators and its relationship to hypotension.

Authors:  G M Tozer; R J Maxwell; J R Griffiths; P Pham
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

Review 8.  Prostanoid Metabolites as Biomarkers in Human Disease.

Authors:  Helena Idborg; Sven-Christian Pawelzik
Journal:  Metabolites       Date:  2022-08-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.